VYZULTA details covers drugs, mechanism of action, dosage and administration, route of synthesis, and pharmacological studies, including product marketed details

VYZULTA Market Forecast VYZULTA drug Insight

&ldquo;VYZULTA, Market Size, Forecast, and Drug Insight &ndash; 2032&rdquo; report provides comprehensive insights about VYZULTA (BOL-303259-X) for Glaucoma in the 7MM. A detailed picture of the VYZULTA (BOL-303259-X) for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019&ndash;2032 is provided in this report along with a detailed description of the VYZULTA (BOL-303259-X) for Glaucoma. The report provides insight about mechanism of action, dosage and administration, as well as research and development activity including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VYZULTA (BOL-303259-X) market forecast, analysis for Glaucoma in the 7MM, descriptive analysis such as SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Glaucoma.

<h2>Drug Summary</h2>

VYZULTA (latanoprostene bunod ophthalmic solution) 0.024% is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. This product was developed by Nicox&rsquo;s. It is the first eye drop approved in 20 years with a novel approach to IOP lowering. VYZULTA helps lower the eye pressure by increasing the drainage of fluid from the eye. It is believed to work through two different pathways in the eye. Thereby, lowering IOP can help reduce the risk of vision loss due to glaucoma.

&nbsp;

Dosage

The recommended dosage is one drop in the conjunctival sac of the affected eye(s) once daily in the evening. VYZULTA (latanoprostene bunod ophthalmic solution), 0.024%, should not be administered more than once daily since it has been shown that more frequent administration of prostaglandin analogs may lessen the IOP lowering effect. If VYZULTA is to be used concomitantly with other topical ophthalmic drug products to lower intraocular pressure, administer each drug product at least five minutes apart.

&nbsp;

Mechanism of Action

VYZULTA contains latanoprostene bunod, and it is thought to lower IOP by increasing the outflow of aqueous humor through both the trabecular meshwork and uveoscleral routes. IOP is a major modifiable risk factor for glaucoma progression. The reduction of IOP reduces the risk of glaucomatous visual field loss.

<h2>Scope of the Report</h2>

The report provides insights into:

<ul>
	<li>&nbsp;A comprehensive product overview including the VYZULTA (BOL-303259-X) description, mechanism of action, dosage and administration, research and development activities in Glaucoma.</li>
	<li>&nbsp;Elaborated details on VYZULTA (BOL-303259-X) regulatory milestones and other development activities have been provided in this report.</li>
	<li>&nbsp;The report also highlights the VYZULTA (BOL-303259-X) research and development activity in Glaucoma in detail across the United States, Europe and Japan.</li>
	<li>&nbsp;The report also covers the patents information with expiry timeline around VYZULTA (BOL-303259-X).</li>
	<li>&nbsp;The report contains forecasted sales of VYZULTA (BOL-303259-X) for Glaucoma till 2032.</li>
	<li>&nbsp;Comprehensive coverage of the late-stage emerging therapies for Glaucoma.</li>
	<li>&nbsp;The report also features the SWOT analysis with analyst views for VYZULTA (BOL-303259-X) in Glaucoma.</li>
</ul>

&nbsp;

<h3>Methodology</h3>

&nbsp;

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight&rsquo;s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

&nbsp;

VYZULTA (BOL-303259-X) Analytical Perspective by DelveInsight

&nbsp;

<ul>
	<li>In-depth VYZULTA (BOL-303259-X) Market Assessment</li>
</ul>

This report provides a detailed market assessment of VYZULTA (BOL-303259-X) in Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2022 to 2032.

&nbsp;

<ul>
	<li>VYZULTA (BOL-303259-X) Clinical Assessment</li>
</ul>

The report provides the clinical trials information of VYZULTA (BOL-303259-X) in Glaucoma covering trial interventions, trial conditions, trial status, start and completion dates.

&nbsp;

<h3>Report Highlights&nbsp;</h3>

<ul>
	<li>&nbsp;In the coming years, the market scenario for Glaucoma is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.&nbsp;&nbsp;</li>
	<li>&nbsp;The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VYZULTA (BOL-303259-X) dominance.</li>
	<li>&nbsp;Other emerging products for Glaucoma are expected to give tough market competition to VYZULTA (BOL-303259-X) and launch of late-stage emerging therapies in the near future will significantly impact the market.</li>
	<li>&nbsp;A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VYZULTA (BOL-303259-X) in Glaucoma.</li>
	<li>&nbsp;Our in-depth analysis of the forecasted sales data of VYZULTA (BOL-303259-X) from 2022 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VYZULTA (BOL-303259-X) in Glaucoma.</li>
</ul>

&nbsp;

<h3>Key Questions</h3>

<ul>
	<li>&nbsp;What is the product type, route of administration and mechanism of action of VYZULTA (BOL-303259-X)?</li>
	<li>&nbsp;What is the clinical trial status of the study related to VYZULTA (BOL-303259-X) in Glaucoma and study completion date?</li>
	<li>&nbsp;What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VYZULTA (BOL-303259-X) development?</li>
	<li>&nbsp;What are the key designations that have been granted to VYZULTA (BOL-303259-X) for Glaucoma?</li>
	<li>&nbsp;What is the forecasted market scenario of VYZULTA (BOL-303259-X) for Glaucoma?</li>
	<li>&nbsp;What are the forecasted sales of VYZULTA (BOL-303259-X) in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?&nbsp;</li>
	<li>&nbsp;What are the other emerging products available in Glaucoma and how are they giving competition to VYZULTA (BOL-303259-X) for Glaucoma?</li>
	<li>&nbsp;Which are the late-stage emerging therapies under development for the treatment of Glaucoma?</li>
</ul>

1. Report Introduction

2. VYZULTA (BOL-303259-X) Overview

2.1. Product Detail

2.2. Clinical Development

2.2.1. Clinical Studies

2.2.2. Clinical Trials Information

2.2.3. Safety and Efficacy

2.3. Regulatory Milestones

2.4. Other Developmental Activities

2.5. Product Profile

3. Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Therapies) *

5. VYZULTA (BOL-303259-X) Market Assessment

5.1. Market Outlook of VYZULTA (BOL-303259-X) for Glaucoma

5.2. 7MM Market Analysis

5.2.1. Market Size of VYZULTA (BOL-303259-X) in the 7MM for Glaucoma

5.3. Country-wise Market Analysis

5.3.1. Market Size of VYZULTA (BOL-303259-X) in the United States for Glaucoma

5.3.2. Market Size of VYZULTA (BOL-303259-X) in Germany for Glaucoma

5.3.3. Market Size of VYZULTA (BOL-303259-X) in France for Glaucoma

5.3.4. Market Size of VYZULTA (BOL-303259-X) in Italy for Glaucoma

5.3.5. Market Size of VYZULTA (BOL-303259-X) in Spain for Glaucoma

5.3.6. Market Size of VYZULTA (BOL-303259-X) in the United Kingdom for Glaucoma

5.3.7. Market Size of VYZULTA (BOL-303259-X) in Japan for Glaucoma

6. SWOT Analysis

7. Analysts&rsquo; Views

8. Appendix

8.1. Bibliography

8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

“VYZULTA, Drug Insight and Market Forecast – 2032” report provides comprehensive insights about VYZULTA (BOL-303259-X) for Glaucoma in the 7MM. A detailed picture of the VYZULTA (BOL-303259-X) for Glaucoma in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019–2032 is provided in this report along with a detailed description of the VYZULTA (BOL-303259-X) for Glaucoma.

Vyzulta (latanoprostene bunod ophthalmic solution) Drug Insight

Vyzulta (latanoprostene bunod ophthalmic solution) - Market Size, Forecast, and Drug Insight - 2032

VYZULTA Drug Insight and Market Forecast- 2032 report by DelveInsight outlays comprehensive insights of the product indicated for the treatment of its approved condition.